Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01147-w
Abstract: Objectives: The study was designed to investigate the safety of ramucirumab administered in combination with erlotinib or osimertinib for patients with untreated EGFR-mutated non–small cell lung cancer (NSCLC) and asymptomatic brain metastases, a patient subgroup… read more here.
Keywords: brain metastases; egfr mutated; asymptomatic brain; erlotinib osimertinib ... See more keywords